Cheers, I agree with some parts of your assessment. However there are a few assumptions that get rehashed repeatedly through this forum that are misleading.
Firstly, Appen’s overall contribution to multinational megatech companies racing toward capitalising on AI, is highly overstated. There a a large network mber of established and emerging training data companies, not to mention the in-house efforts by many of the mega-tech entities.
Secondly, a business’s profits come from efficient and streamlined processes, and frankly Appen’s training data sourcing and contracts are a bit of a dogs breakfast.
Lastly, in order to remain relevant in a rapidly evolving field, it is critical that Appen stay at least a few steps ahead of the game. Instead, Appen is struggling to stay relevant as they fell asleep at the wheel and have been on the backfoot since. I think you’ll find over the coming years, Appen is going to be less and less of a main player in this sphere. It also does not have any real diversification as a company, so a significant risk from a lack of a business ‘moat’.
The moment it requires a capital raise or to take on debt in this high interest period, it is finished as a company, as I believe it will struggle to stay relevant [enough] to improve its cash flow position and hence maintain profitability. A CEO reshuffle in the middle of this highly competetive period further adds to its woes lagging the competition.
Just my two cents in summary.
- Forums
- ASX - By Stock
- $4 party!
Cheers, I agree with some parts of your assessment. However...
-
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add APX (ASX) to my watchlist
|
|||||
Last
50.0¢ |
Change
-0.005(0.99%) |
Mkt cap ! $111.5M |
Open | High | Low | Value | Volume |
51.0¢ | 53.0¢ | 49.0¢ | $1.034M | 2.032M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 25178 | 50.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
51.0¢ | 26979 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 25178 | 0.500 |
4 | 52371 | 0.495 |
15 | 360117 | 0.490 |
7 | 101980 | 0.485 |
10 | 470902 | 0.480 |
Price($) | Vol. | No. |
---|---|---|
0.510 | 26979 | 3 |
0.515 | 15117 | 2 |
0.520 | 73197 | 6 |
0.525 | 20811 | 2 |
0.530 | 140339 | 6 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
APX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online